Role of nucleic acid-based polymeric micelles in treating lung diseases / Jaskiran Kaur, Monica Gulati, Leander Corrie, Ankit Awasthi, Niraj Kumar Jha, Dinesh Kumar Chellappan, Gaurav Gupta, Ronan MacLoughlin, Brian G Oliver, Kamal Dua, Sachin Kumar Singh
The prevalence of lung diseases is increasing year by year and existing drug therapies only provide symptomatic relief rather than targeting the actual cause. Nucleic acids can be used as an alternative therapeutic approach owing to their potential to reform a homeostatic balance by upregulating protective genes or downregulating damaging genes. However, their inherent properties, such as poor stability, ineffective cellular uptake, negative charge and so on, hinder their clinical utility. Such limitations can be overcome by exploiting the functional chemistry of polymeric micelles (PMs) for site-specific delivery, transfection efficiency and improved stability. With this objective, the present work describes the advancements made in designing nucleic acid-based PMs for treating lung diseases followed by approaches requiring consideration for clinical applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2023 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaur, Jaskiran [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Functionalization |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| doi: |
10.2217/nnm-2022-0260 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011096128 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011096128 | ||
| 003 | DE-627 | ||
| 005 | 20230713210644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2022-0260 |2 doi | |
| 035 | |a (DE-627)KFL011096128 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2022-0260 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Kaur, Jaskiran |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of nucleic acid-based polymeric micelles in treating lung diseases |c Jaskiran Kaur, Monica Gulati, Leander Corrie, Ankit Awasthi, Niraj Kumar Jha, Dinesh Kumar Chellappan, Gaurav Gupta, Ronan MacLoughlin, Brian G Oliver, Kamal Dua, Sachin Kumar Singh |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2023 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The prevalence of lung diseases is increasing year by year and existing drug therapies only provide symptomatic relief rather than targeting the actual cause. Nucleic acids can be used as an alternative therapeutic approach owing to their potential to reform a homeostatic balance by upregulating protective genes or downregulating damaging genes. However, their inherent properties, such as poor stability, ineffective cellular uptake, negative charge and so on, hinder their clinical utility. Such limitations can be overcome by exploiting the functional chemistry of polymeric micelles (PMs) for site-specific delivery, transfection efficiency and improved stability. With this objective, the present work describes the advancements made in designing nucleic acid-based PMs for treating lung diseases followed by approaches requiring consideration for clinical applications | ||
| 653 | |a functionalization | ||
| 653 | |a nucleic acids | ||
| 653 | |a polymeric micelles | ||
| 653 | |a pulmonary delivery | ||
| 700 | 1 | |a Gulati, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Corrie, Leander |e verfasserin |4 aut | |
| 700 | 1 | |a Awasthi, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Niraj Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Chellappan, Dinesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |e verfasserin |4 aut | |
| 700 | 1 | |a MacLoughlin, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Oliver, Brian G |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sachin Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2022-0260 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||